Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Equillium Inc EQ

Healthcare Biotechnology
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:EQ)

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 3, 2024

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Business Wire April 1, 2024

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Business Wire March 25, 2024

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

Business Wire March 22, 2024

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Business Wire December 21, 2023

EQ Bank Card launches in Québec as Carte Banque EQ

PR Newswire November 20, 2023

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Business Wire November 13, 2023

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Business Wire November 8, 2023

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Business Wire November 6, 2023
View More News ››

Opinion & Analysis (NDAQ:EQ)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:EQ)

Strong Hold!

HUGE news! New partnership with Ono, a leading Japanese pharmaceutical company to further itolizumab!! the potential of itolizumab is...
Shanemorg58 - December 6, 2022

RE:RE:Bang zoom

JohnTool321 - August 5, 2022

RE:RE:Bang zoom

SusanBolland - July 11, 2022

RE:RE:Bang zoom

Lisagerrard17 - July 8, 2022

RE:RE:Bang zoom

Those T cells can be tricky.
Joe455 - May 30, 2022

RE:Bang zoom

GassXX - May 29, 2022
View more Bullboard ››

Mandalay Resources Corp.

Mandalay Resources Corp.

Mandalay Resources Corporation is a Canada-based natural resource company with producing assets in Australia (Costerfield ...
View More »